—
The report provides comprehensive information on the Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics development and features dormant and discontinued projects.Get Sample Report @ https://www.wiseguyreports.com/sample-request/731483-fatty-acid-amide-hydrolase-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape for Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99)
- The report reviews Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Overview 7
Therapeutics Development 8
Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Products under Development by Stage of Development 8
Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Products under Development by Therapy Area 9
Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Products under Development by Indication 10
Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Products under Development by Companies 13
Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Products under Development by Universities/Institutes 15
Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Companies Involved in Therapeutics Development 22
Advinus Therapeutics Ltd 22
Johnson & Johnson 23
MAKScientific, LLC 24
Midatech Pharma US Inc. 25
Takeda Pharmaceutical Company Limited 26
Zynerba Pharmaceuticals, Inc. 27
Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Drug Profiles 28
AM-3506 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
AM-5206 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
IPI-940 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
JNJ-40413269 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
KRN-5500 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 35
Product Description 35
Access Report @ https://www.wiseguyreports.com/reports/731483-fatty-acid-amide-hydrolase-review-h2-2016
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349
Website: http://www.wiseguyreports.com
Release ID: 144563
Google
RSS